Rosacea treatments: an overview.

While there is no cure for rosacea, there are treatments available to address the symptoms.

Topical creams and gels
Applied to the skin once or twice a day to treat redness, bumps and pimples. Often used with oral antibiotics and continued long term to maintain control of symptoms.
Oral antibiotics
Help to control redness, bumps and pimples. Often used short term along with topical creams to bring symptoms under control, but sometimes they may be used long term.
Oral isotretinoin
Usually used for acne, sometimes prescribed for severe rosacea that is resistant to other treatment.
Laser and intense
pulsed light
Help to relieve redness and target visible blood vessels in the face, chest and neck areas.
Photodynamic therapy (PDT)
Combines light therapy with a sensitizing liquid applied to the skin that is activated by the light. Reduces inflammation and pimples and improves skin texture.
Glycolic peels
May improve rosacea symptoms in some people when used in addition to standard treatments.
In some cases, different types of surgery have been used to remove excess tissue from the nose in patients with rhinophyma.

Finacea® (azelaic acid) Gel, 15% is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation. Finacea® and its vehicle caused irritant reactions at the application site in human dermal safety studies. Skin irritation (e.g. pruritus, burning or stinging) may occur during use with Finacea®, usually during the first few weeks of treatment. If sensitivity or severe irritation develops and/or persists during use with Finacea®, discontinue use and institute appropriate therapy.

In clinical trials with Finacea®, the most common local adverse events (AE's) were: burning/stinging/tingling (29%), pruritus (11%), scaling/dry skin/xerosis (8%) and erythema/irritation (4%). Contact dermatitis, edema and acne were observed at frequencies of 1% or less. Rarely reported AE's included: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris) and exacerbation of recurrent herpes labialis. Post-marketing safety information: Skin (facial burning and irritation); Eyes (iridocyclitis on accidental exposure with Finacea® to the eye). To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-866-463-3634 or FDA at 1-800-FDA-1088 or

Finacea® is for topical use only. It is not for ophthalmic, oral or intravaginal use. In case of accidental eye exposure, wash eyes with large amounts of water and consult a physician if eye irritation persists. Wash hands following application of Finacea®.

See Full Prescribing Information for Finacea® at

Click here to return to

You are about to leave Are you sure you want to leave?